Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
Sep 12, 2018 · After transitioning from 3 mg/kg Q2W to 480 mg Q4W, 14.8% of patients reported treatment-related adverse events and 1.6% of patients reported grade 3 or grade 4 treatment-related adverse events.
SABCS 2024: Improving Treatment for Early Breast Cancer
Dec 20, 2024 · Kuemmel S, Gluz O, Nitz U, et al. (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET-response ...
Paclitaxel and Nab-Paclitaxel Deemed Comparable for High-Risk …
Dec 14, 2024 · References: Kuemmel S, Gluz O, Nitz U, et al. (Neo)adjuvant nab-PAC weekly vs sb-PAC q2w, followed by EC q2w, in genomically or clinically high-risk HR+/HER- early breast cancer according to ET ...
Talquetamab Elicits Responses in Relapsed/Refractory Multiple …
In the 0.8 mg/kg Q2W group, the median age at baseline was 67 years (range, 38 to 84), and 86.2% of patients were White. The patients had received a median of 5 prior lines of therapy (range, 2 to ...
ASH 2022: Promising Results in Newly Diagnosed and …
In the Q2W dosing group, the median follow-up for efficacy was 8.6 months. The ORR was 73.1%, 12.4% of patients achieved a CR, and 20.0% achieved an sCR. The median duration of response was 13.0 ...
SC Amivantamab Offers Similar Efficacy, Greater Convenience …
Results with subcutaneous (SC) amivantamab compared favorably to results with intravenous (IV) amivantamab in the PALOMA-3 trial, according to data presented at the ASCO Annual Meeting 2024. 1 ...
mFLOT/TFOX Regimen Bests FOLFOX in Gastric/GEJ …
Docetaxel plus oxaliplatin and 5-fluorouracil (mFLOT/TFOX) is more effective than oxaliplatin and 5-fluorouracil (FOLFOX) for patients with advanced gastric or gastroesophageal junction (GEJ ...
RELAY Phase 3: Efficacy of the Addition of Ramucirumab to …
Jun 14, 2019 · A total of 449 patients (77% Asian, 63% female, 55% had an exon 19 deletion [vs exon 21 L858R substitution mutation]) were randomly selected in a 1:1 ratio to receive 1 of the 2 treatment arms.
Nivolumab Plus Cabozantinib Improves Outcomes Relative to …
Nov 6, 2021 · A total of 651 patients with clear cell aRCC were randomly assigned (1:1) to receive nivolumab plus cabozantinib (240 mg Q2W; 40 mg QD) or sunitinib (50 mg QD for 4 weeks of 6-week cycles).
Multiple Myeloma and Infections: Characterizing the Risks
Mar 18, 2019 · The therapeutic landscape in multiple myeloma (MM) has significantly expanded since the development of immunomodulatory agents such as thalidomide. These include newer immunomodulatory agents such ...